Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.32
-2.14 (-0.80%)
AAPL  308.82
+3.83 (1.26%)
AMD  467.51
+17.92 (3.99%)
BAC  51.80
+0.31 (0.60%)
GOOG  379.38
-4.09 (-1.07%)
META  610.26
+2.88 (0.47%)
MSFT  418.57
-0.52 (-0.12%)
NVDA  215.33
-4.18 (-1.90%)
ORCL  192.08
+2.31 (1.22%)
TSLA  426.01
+8.16 (1.95%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.